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Abstract
Several cases of Multisystem Inﬂammatory Syndrome in Adults (MIS-A) have been reported in adults since June 2020
after COVID-19 was ﬁrst reported in December 2019. It was initially reported in children as MIS-C with Kawasaki-like
disease, but a similar condition has been well recognized in adults. Although Mycoplasma co-infection has been reported with COVID-19, to our knowledge, concomitant Mycoplasma pneumoniae infection has not been reported
together with MIS-A. We present a case of MIS-A with concomitant M. pneumoniae infection. It is unclear if concomitant
Mycoplasma infection resulted in increased severity of the patient's illness or if it resulted in inciting the immune
response in our patient who had recently recovered from COVID-19 infection. This case highlights the need to diagnose
a patient with a typical presentation of MIS-A and any concomitant infection or illnesses.
Keywords: Multisystem inﬂammatory disorder, MIS-A, Mycoplasma, Infection, COVID-19, Coronavirus, Kawasaki-like
disease

1. Introduction

C

OVID 19 illness has resulted in a global
pandemic causing more than 380 million
cases globally and more than 75 million cases in
the US alone.1 Multisystem inﬂammatory syndrome in children (MIS-C) is a rare but severe
condition in children and adolescents infected with
SARS-CoV-2.2 Since June 2020, there have been
several reports of a similar multisystem inﬂammatory syndrome in adults (MIS-A).3e9 We did
literature review for cases of MIS-A and concomitant Mycoplasma infection in databases such as
PubMed, Google Scholar and Cochrane review for
cases written in English language using terms
“MIS-A00 , “COVID-19” and “Mycoplasma”. We
were unable to ﬁnd any reported cases. Here, we

present a case of MIS-A with concomitant Mycoplasma pneumoniae infection.

2. Case presentation
A healthy 22-year-old Hispanic male with no
signiﬁcant past medical history presented to the
emergency room (ER) with fever, neck pain, redness
of eyes, and abdominal pain of two days. He was
diagnosed with COVID-19 infection ﬁve weeks prior
to the presentation. After the complete resolution of
his symptoms and two negative COVID-19 polymerase chain reaction (PCR) tests, he had returned
to his work.
On presentation to ER, the vitals were blood
pressure of 114/65 mmHg, heart rate of 96 beats per
minute, temperature of 100.8 Fahrenheit, respiratory
rate of 16 and oxygen saturation of 100%.
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He was found to have non-purulent conjunctivitis,
cervical
lymphadenopathy,
thrombocytopenia,
elevated bilirubin, mildly elevated liver function
tests (LFTs). The Mononucleosis screen test (Monospot) for heterophile antibodies was negative. He
was prescribed azithromycin and prednisone and
was discharged from ER.
The next day, he presented back to the ER with
persistent fevers, neck pain, trismus, generalized
body ache, abdominal pain, and redness of eyes. He
was febrile with a temperature of 103.7 Fahrenheit,
tachycardic with a heart rate of 125 beats per minute, his respiratory rate was 18 and blood pressure
was 100/50 mmHg. On physical examination, he had
cervical lymphadenopathy and non-purulent
conjunctivitis. The rest of the physical examination
was unremarkable. The laboratory workups
revealed lymphopenia, thrombocytopenia, hyponatremia, elevated bilirubin, and mildly elevated LFTs.
His COVID-19 PCR was positive in the respiratory
viral panel; however, the nasal SARS-CoV-2 antigen
test was negative. The rest of the laboratory workup
was unremarkable, as shown in Table 1. Additional
workup including mononucleosis screen, Group A
Streptococcus, HIV 1 and 2 Antigen, antibody tests,
and hepatitis panel were negative. CT neck revealed
cervical lymphadenopathy (Fig. 1). Chest X-ray was
unremarkable. US abdomen revealed increased
echogenicity along portal veins, gallbladder sludge,
normal caliber hepatic ducts, negative Murphy's
sign. He was continued on prednisone and azithromycin and admitted to the medical ﬂoor.

Fig. 1. Level II cervical lymphadenopathy in CT soft tissue neck.

On day 2, his fever persisted, and he developed
hypoxia requiring 1e2 Liter/min oxygen via nasal
cannula. He also developed hypotension and
required intravenous ﬂuids and subsequently
norepinephrine to maintain the blood pressure. His
hypoxia gradually worsened, requiring 12 L/min
oxygen via a hi-ﬂow nasal cannula. Repeat laboratory workups revealed persistent thrombocytopenia, elevated LFTs, elevated inﬂammatory
markers-elevated d dimer, CRP, ferritin, and procalcitonin (Table 1). Blood cultures showed no
growth. Peripheral smear showed normochromic

Table 1. The laboratory workup during hospitalization.
WBC count
Neutrophil count
Lymphocyte count
Hemoglobin
Platelet count
Sodium
Potassium
Calcium
Blood Urea Nitrogen
Creatinine
Total bilirubin
Aspartate aminotransferase
Alanine aminotransferase
Alkaline phosphatase
International normalized ratio
C-Reactive protein
D-dimer
Ferritin
Procalcitonin
Troponin, hs
Brain natriuretic peptide
Lactic acid
N/C*- Not Checked.

Ref range

Day 1

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7

4e10  1000/cmm
1.6e8  1000/cmm
0.8e4.5  1000/cmm
13.5e17 g/dL
150e450  1000/cmm
135-146 mEq/L
3.5e5.3 mEq/L
8.5e10.4 mg/dL
7e25 mg/dL
0.7e1.3 mg/dL
0.1e1.5 mg/dL
2e50 U/L
2e60 U/L
20e125 U/L
0.9e1.1
<0.8 mg/dL
<230 ng/mL
20e345 ng/mL
<0.1 ng/mL
<53 ng/L
0e100 pg/mL
0.5e2 mmol/L

7.7
6.8
0.4
14.1
73
130
3.8
9.3
16
1.3
5.8
59
87
134
N/C*
N/C*
N/C*
N/C*
N/C*
N/C*
N/C*
1.3

7.6
6.7
0.7
12.8
58
136
4.2
7.8
20
1.2
6.2
63
81
118
1.41
23.7
2241
1547
5.91
169
1072
N/C*

9.6
8.4
0.9
12.5
82
138
4.2
8.1
21
0.8
2.9
125
133
106
1.24
24.9
1376
1970
N/C*
110
N/C*
N/C*

9.4
7.8
1.3
13.4
121
136
4.0
8.2
29
0.9
1.8
79
141
94
N/C*
13.5
841
1993
1.47
N/C*
N/C*
N/C*

9.2
6.8
1.5
12.9
117
135
4.2
7.8
27
0.9
1.8
113
169
87
N/C*
7.2
821
N/C*
0.78
N/C*
N/C*
N/C*

10.1
6.5
2.5
13.7
144
136
4.1
7.6
25
0.9
1.4
66
160
109
N/C*
N/C*
N/C*
N/C*
0.42
N/C*
N/C*
N/C*

11.5
7.1
3.4
13.3
186
136
3.8
7.8
22
0.8
1.3
55
155
108
N/C*
2.9
N/C*
933
0.25
N/C*
N/C*
N/C*

Fig. 2. CT chest with alveolar and interstitial edema, bilateral posterior
lower lobe consolidations, bilateral pleural effusions.

normocytic anemia, absolute lymphopenia, and
thrombocytopenia without evidence of microangiopathic hemolytic anemia. The M. pneumoniae
IgM was noted to be positive. Due to worsening
hypoxia, a CT angiogram of the chest was done,
which revealed pulmonary vascular congestion with
alveolar and interstitial edema, bilateral posterior
lower lobe consolidations, moderate right and small
left pleural effusions but no evidence of pulmonary
embolism (Fig. 2). Bilateral lower and upper extremities duplex was negative. He developed atrial
ﬁbrillation with a rapid ventricular response (Fig. 3
and converted to sinus rhythm after receiving
intravenous metoprolol. He was started on broadspectrum antibiotics piperacillin-tazobactam and
vancomycin.
On day 3, his condition continued to worsen with
persistent fever, tachycardia, hypoxia, hypotension
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requiring norepinephrine, cervical lymphadenopathy, trismus, non-purulent conjunctivitis, lymphopenia,
thrombocytopenia,
elevated
cardiac
biomarkers including troponin, brain natriuretic
peptide, elevated inﬂammatory markers including
CRP, D-dimer, ferritin, procalcitonin. These ﬁndings were concerning for MIS-A, and intravenous
immunoglobulin (IVIG) 25 g was administered. He
was continued on vancomycin, piperacillin-tazobactam, azithromycin, and steroids. Vancomycin
was later discontinued after MRSA nasal screen was
negative.
On day 4, the patient had a signiﬁcant improvement; he was weaned off norepinephrine, and oxygen was weaned off to room air as well. He had
improvement in his white blood cell counts,
lymphocyte counts, inﬂammatory markers and
platelet counts along with bilirubin (see Fig.4,
Fig. 5). He continued to improve signiﬁcantly over
the next three days and was discharged on day 7. He
was discharged on a tapering dose of dexamethasone to be completed over the next two weeks. On
post-discharge follow-up in two weeks, he had
complete resolution of his symptoms.

3. Discussion
Center of Disease Control (CDC) deﬁnes MIS-A
as a patient aged 21 years hospitalized for 24 h,
or with an illness resulting in death, who meets the
following clinical and laboratory criteria. The patient should not have a more likely alternative
diagnosis for the illness (e.g., bacterial sepsis, exacerbation of a chronic medical condition).10

Fig. 3. EKG with atrial ﬁbrillation and rapid ventricular response.
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Fig. 4. The trend of inﬂammatory markers during hospitalization.

Fig. 5. The trend of platelets and lymphocyte counts during hospitalization.

3.1. Clinical criteria
 Subjective fever or documented fever (38.0 C)
for 24 h prior to hospitalization or within the
ﬁrst 3 days of hospitalization and at least 3 of the
following clinical criteria occurring prior to
hospitalization or within the ﬁrst 3 days of hospitalization. At least 1 must be a primary clinical
criterion.
ο Primary clinical criteria
1. Severe cardiac illness-Includes myocarditis, pericarditis, coronary artery dilatation/aneurysm, or new-onset right or left
ventricular dysfunction (LVEF<50%), 2nd/

3rd degree A-V block, or ventricular
tachycardia
2. Rash and non-purulent conjunctivitis
 Secondary clinical criteria
1. New-onset
neurologic
signs
and
symptoms-Includes encephalopathy in a
patient without prior cognitive impairment, seizures, meningeal signs, or
peripheral neuropathy (including GuillainBarr
e syndrome)
2. Shock or hypotension not attributable to
medical therapy (e.g., sedation, renal
replacement therapy)
3. Abdominal pain, vomiting, or diarrhea

4. Thrombocytopenia
<150,000/microliter)

(platelet

count

3.2. Laboratory evidence
 The presence of laboratory evidence of inﬂammation and SARS-CoV-2 infection.
ο Elevated levels of at least 2 of the following:
CRP, ferritin, IL-6, erythrocyte sedimentation
rate, procalcitonin
ο A positive SARS-CoV-2 test for current or
recent infection by RT-PCR, serology, or antigen detection
Our patient met criteria for MIS-A with documented
fever, cardiac illness with myocarditis and atrial ﬁbrillation with a rapid ventricular response, non-purulent
conjunctivitis, hypotension/shock not attributable to
medical therapy requiring norepinephrine, abdominal
pain, thrombocytopenia, elevated inﬂammatory
markers including CRP, ferritin and procalcitonin and
evidence of recent COVID-19 infection around ﬁve
weeks prior to presentation. Other possible causes for
this type of presentation were ruled out with diligent
workup and testing. Additional workup for bacterial
superimposition was done and our patient was found to
have a concomitant M. pneumoniae infection. Antibiotic
therapy with macrolides, ﬂuoroquinolones, or tetracyclines is the mainstay of treatment for Mycoplasma
pneumonia.11 Current data from CDC suggest that the
prevalence of macrolide resistance in M. pneumoniae
may be around 10% in the United States, with regional
variability.11 Hence our patient was treated with
azithromycin.
Although Mycoplasma co-infection has been reported with COVID-19, to our knowledge,
concomitant M. pneumoniae infection has not been
reported together with MIS-A.12 However, Mycoplasma co-infection has been reported together with
Multisystem Inﬂammatory Syndrome in Children
(MIS-C).13 It has been shown that M. pneumoniae coinfection in pediatric patients with MIS-C may
contribute to a more severe clinical course.13 It is
unclear whether Mycoplasma infection incited an
immune response or if concomitant Mycoplasma
infection caused the symptoms and clinical picture
to be more severe in our patient. Further studies are
needed to understand more about MIS-A and any
potential inciting factors, including infection, that
could result in the multisystem inﬂammatory
response in a patient with recent COVID-19 infection with subsequent recovery. It is prudent to diagnose concomitant illnesses or infections in a
patient with MIS-A and treat them appropriately.
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4. Conclusion
It is important to diagnose MIS-A in a patient with
a delayed immunologic response to SARS-CoV-2
infection in adults with hyperinﬂammation. The
treatment mainly includes corticosteroids and IVIG,
along with supportive management. It is also
important to diagnose any concomitant infection or
illnesses and treat them accordingly. More studies
are needed to understand more about this phenomenon and understand if there are any factors
such as an infection or illnesses inciting an immune
response resulting in multisystem inﬂammatory
disorder.
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